Intas Receives Warning Letter from USFDA Over Data Integrity and Quality Concerns at Dehradun Facility

Intas Pharmaceuticals Faces Renewed Regulatory Pressure in the US

The Food and Drug Administration (FDA) has issued a warning letter to Intas Pharmaceuticals' Dehradun facility, citing serious lapses in quality systems and data integrity that could impact its key export business. The warning letter, issued on March 30, 2026, following a September 2025 inspection, highlights manufacturing practices that failed to comply with good manufacturing norms, rendering its products "adulterated" under US law.

The FDA's concerns center around Intas' handling of out-of-specification (OOS) results, including repeated stability failures in tablet products and inadequate investigations. The regulator also criticized the company for invalidating test results without sufficient evidence and failing to establish whether deviations were due to flawed analytical methods or actual product degradation.

The warning letter was made public by the USFDA on April 28, 2026. While a warning letter may not affect existing supplies, it will put a lid on new approvals, which are critical to growth for generic companies operating in the US.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

Intas will need to address the compliance violations identified in the warning letter, or the agency may block imports into the US market. The US constituted around 5 percent of Intas' total revenue of Rs. 20,844 crore in FY25, according to rating firm CareEdge. The US is an important market, where the company has been investing significantly.

The USFDA also criticized the firm for data integrity lapses, stating that a quality assurance employee directed a software vendor to alter electronic batch records without audit trail documentation. Key changes, including modifications to personnel identification entries, were neither recorded nor subject to proper quality oversight, while existing procedures failed to ensure control over post-record changes.

USFDA Criticisms of Intas' Quality Systems

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year

The latest action adds to Intas' broader regulatory challenges. The USFDA issued an import alert to Intas's manufacturing facility in Pharmez SEZ, Ahmedabad (Gujarat) in June 2023, and another import alert for its Matoda facility in Ahmedabad in November of that year.

The USFDA has asked the company to undertake a comprehensive overhaul of its quality systems, including independent third-party assessments and stronger controls on investigations and data integrity. Intas has been given 15 working days to respond with a detailed remediation plan, with its ability to sustain US market access hinging on restoring compliance credibility.